Bayer AG

Bayer is a global enterprise with core competencies in the Life Science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, realiability and quality throughout the world.
At Pharmaceuticals, our largest segment in terms of sales, we focus on researching, developing and marketing specialty-focused innovative medicines that provide significant clinical benefit and value, primarily in the therapeutic areas of cardiology, oncology, gynecology, hematology and ophthalmology. The division also comprises the radiology business, which markets diagnostic imaging equipment together with the necessary contrast agents. In this way, we are addressing the growing requirements of patients, physicians, health care payers and regulatory agencies.
Bayer considers human pluripotent stem cells and stem cell-derived cardiomyocytes a valuable and promising tool in the drug discovery process, especially in the target identification and validation.

More information: »

In the initial EBiSC phase, Bayer contributed to the proof-of-concept studies and provided expert advice. In EBiSC2, Bayer continues its contributions to functional testing of hiPSC-derived cardiomyocytes and assessing the maturity as well as reproducibility / viability of these cells after upscaling and cryopreservation.